Teleflex to close Minnesota facility, cut 101 employees
Teleflex will close a manufacturing facility in Maple Grove, Minnesota, by next March and cut more than 100 employees as a result.
The planned closure will affect an expected 101 positions, according to a Tuesday Worker Adjustment and Retraining Notification filing obtained by MedTech Dive. The Minnesota Star Tribune first reported the cuts.
Most laboratory and manufacturing operations are expected to cease by June 30, with the layoffs occurring on July 1, according to the filing. Teleflex did not respond to a request for comment on why it was closing the Maple Grove facility.
In February, Teleflex announced it would split into two separate, public entities. A new company would comprise Teleflex's urology, acute care and OEM businesses, while the remaining company would include the vascular access, interventional and surgical businesses. Simultaneously, Teleflex bought Biotronik's vascular intervention division.
Teleflex aims to streamline manufacturing during the restructuring. The company aims to reduce the number of facilities from the combination of Biotronik and the remaining company from 19 facilities to seven, CEO Liam Kelly told investors in February.
The Maple Grove site was used to make diagnostic and interventional catheters, according to the company's website. Teleflex's remaining company had pro forma revenue of $2.1 billion in 2024 with the Biotronik acquisition.
Recommended Reading
Teleflex to split in 2, buy Biotronik assets for $791M among slew of actions
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 days ago
- Yahoo
Medical device industry says future MDUFA hikes unsustainable
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Medical device companies advocated against future increases to user fees at a public hearing Monday for the next medical device user fee amendments. Meanwhile, Food and Drug Administration leaders, facing congressional budget cuts, made a case for more user fees, emphasizing the importance of the program. The five-year agreement determines the amount the FDA can raise from the medtech industry to supplement congressional appropriations. In the current MDUFA program, which ends in September 2027, the FDA's device center negotiated a boost in user fee funding in exchange for meeting certain review timelines and staffing levels. The next agreement would take effect in October 2027 and run through 2032. Michelle Tarver, director of the FDA's Center for Devices and Radiological Health, said the FDA 'requires sustained and increased investment by the medical device industry' to meet its goals. The device leader added that 'holding steady does not lead to excellence — it leads to mediocrity.' However, device industry lobbyists at the meeting indicated a preference for few changes. 'Each MDUFA cycle included significant resources and investments, including increasing the number of [full-time employees] to support the program,' said Janet Trunzo, senior executive vice president of technology and regulatory affairs for AdvaMed. 'Now that we have approached nearly 25 years … of user fee programs for medical devices, we are now in a position of merely fine-tuning the current program.' Mark Leahey, CEO of the Medical Device Manufacturers Association, called for the process to return 'back to the basics' in comments on Monday. Leahey said the funds from MDUFA should go to reviewers and medical officers, and added that the industry wants more visibility as to where the funds are going and 'where people are right now, realizing there's been some attrition over the last six months.' Citing the latest user fee rates, Leahey said more than $427 million in fees were authorized for fiscal year 2026. 'We have to realize the size and scope of the investments here,' he said. 'And this is not a sustainable pathway.' The meeting kicked off a process where the FDA will seek public comment through Sept. 4, before beginning negotiations with industry. When a final agreement is reached, the FDA will present it to Congress, which must approve the next MDUFA program. The negotiations come during a period of uncertainty, where several leaders have left the FDA under Health and Human Services Secretary Robert F. Kennedy Jr. The Trump administration's slashing of probationary FDA employees in February — followed by rehiring some staffers, and then more firings in April — raised questions about whether the FDA's user fees programs could be at risk. FDA Commissioner Marty Makary has suggested lowering user fees for prescription drugs; however, he has not indicated any major changes to medical device fees, referring to MDUFA as 'the best of all the user fee arrangements' during the meeting. Patient advocates call for more fees, transparency While industry pushed back against further fee increases, patient groups called for more fees to offset federal budget cuts to the FDA. Diana Zuckerman, president of the National Center for Health Research, said that given recent cuts in FDA staffing and the importance of speedy device reviews, 'it's inevitable that improving quality requires increasing the fees.' Zuckerman said that while she would like to see Congress provide enough appropriations for the FDA's device center, 'we want to make sure that there's funding for everything that's needed, and, unfortunately, appropriations isn't making that possible.' Zuckerman also called for user fees to be used for postmarket device safety, as well as for more transparency during the negotiation process, positions that were supported by other patient advocates during the meeting. In the past, user fee negotiations have been behind closed doors, and patients, consumers and health professionals have not been able to join or observe the meetings, Zuckerman said. In the last round of negotiations, the FDA also faced scrutiny for not publishing meeting minutes from its conversations with industry in a timely fashion. 'At the very least, we should have access to remotely watch those negotiations, instead of just depending on minutes that are often vague or very delayed so that stakeholders have no opportunity for meaningful input,' said Tess Robertson-Neel, on behalf of the Patient, Consumer, & Public Health Coalition, a group of more than two dozen nonprofits. Robertson-Neel added that user fees should be increased, and the FDA should focus on being 'more patient-centered and transparent and less cozy with industry.' Alexander Naum, policy manager for Generation Patient, a nonprofit representing young adults living with chronic medical conditions, said that user fees must increase and the next MDUFA agreement should include clear postmarket device safety performance goals. He also asked for the FDA to commit funds to expanding its program for tracking medical device adverse events. Naum cited a statistic that the FDA receives more than 2 million reports annually of suspected device malfunctions, serious injuries or deaths. 'So many of us rely on medical devices for our survival,' Naum said. 'Many of these devices present the potential of unexpected adverse events.' Recommended Reading FDA schedules first public MDUFA VI meeting ahead of negotiations Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Yahoo
LeMaitre (LMAT) Reports Q2: Everything You Need To Know Ahead Of Earnings
Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be reporting results this Tuesday after market close. Here's what to expect. LeMaitre beat analysts' revenue expectations by 3.7% last quarter, reporting revenues of $59.87 million, up 12% year on year. It was a satisfactory quarter for the company, with an impressive beat of analysts' organic revenue estimates but a miss of analysts' EPS estimates. Is LeMaitre a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting LeMaitre's revenue to grow 12.1% year on year to $62.58 million, in line with the 11.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.57 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. LeMaitre has missed Wall Street's revenue estimates three times over the last two years. Looking at LeMaitre's peers in the surgical equipment & consumables - specialty segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Teleflex delivered year-on-year revenue growth of 2.3%, beating analysts' expectations by 1.3%, and Intuitive Surgical reported revenues up 21.4%, topping estimates by 3.7%. Teleflex traded up 1.7% following the results while Intuitive Surgical was down 1.9%. Read our full analysis of Teleflex's results here and Intuitive Surgical's results here. Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the surgical equipment & consumables - specialty stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. LeMaitre is down 2.3% during the same time and is heading into earnings with an average analyst price target of $104.50 (compared to the current share price of $81.04). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
6 days ago
- Yahoo
Teleflex Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
The quarterly results for Teleflex Incorporated (NYSE:TFX) were released last week, making it a good time to revisit its performance. It looks like a credible result overall - although revenues of US$781m were what the analysts expected, Teleflex surprised by delivering a (statutory) profit of US$2.77 per share, an impressive 46% above what was forecast. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Teleflex after the latest results. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. After the latest results, the 13 analysts covering Teleflex are now predicting revenues of US$3.32b in 2025. If met, this would reflect a meaningful 9.2% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to shoot up 83% to US$7.97. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$3.13b and earnings per share (EPS) of US$8.42 in 2025. So it's pretty clear consensus is mixed on Teleflex after the latest results; whilethe analysts lifted revenue numbers, they also administered a minor downgrade to per-share earnings expectations. See our latest analysis for Teleflex The analysts also cut Teleflex's price target 5.1% to US$142, implying that lower forecast earnings are expected to have a more negative impact than can be offset by the increase in revenue. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Teleflex, with the most bullish analyst valuing it at US$200 and the most bearish at US$120 per share. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable. Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. The analysts are definitely expecting Teleflex's growth to accelerate, with the forecast 19% annualised growth to the end of 2025 ranking favourably alongside historical growth of 4.0% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 8.2% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Teleflex to grow faster than the wider industry. The Bottom Line The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Teleflex. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of Teleflex's future valuation. With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Teleflex analysts - going out to 2027, and you can see them free on our platform here. However, before you get too enthused, we've discovered 2 warning signs for Teleflex that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
